GANX Gain Therapeutics Inc
P/E
--
Forward P/E
--
Price/Sales
255.5
Beta
0.194
Div Yield
--
Market Cap
--
Company Analysis
Latest News
đź”´ Gain Therapeutics is trading 10% down amid biotech-sector weakness
Gain Therapeutics is trading at $1.41, down 10.18%, with no confirmed company-specific catalyst identified. - The supplied market context reports XBI down...
đź”´ Gain Therapeutics is trading 5% down today amid broader biotech weakness
Gain Therapeutics is trading 5.1% lower now at $1.49, with broader biotech weakness providing context; no company-specific catalyst is confirmed. - XBI was...
Gain Therapeutics Reports 12-Month Stable Motor Scores in Parkinson’s Study
On October 1, 2026, Gain Therapeutics announced positive long-term data from the Phase 1b open-label extension study of rexaceract in patients with Parkinson’s...